Gossamer Bio Inc
Gossamer Bio Inc (GOSS) Covered Calls
Gossamer Bio Inc trades in the Biotechnology industry with an IV Rank of 42.26%, average versus the past year. GOSS's highest covered call setup is the $1.00 strike expiring Jan 21, 2028, sorted by theoretical annualized return. It's 614.29% out of the money with 498 days to expiration, a 650.00% return until expiration, and a 476.41% theoretical annualized return. Across the setups shown, annualized returns run from 214.64% to 476.41% at strikes between $0.50 and $1.00, with 498 to 498 days to expiration, as of Sep 10, 2026.
Read more
Running GOSS covered calls helps you generate income from Gossamer Bio Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best GOSS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If GOSS stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling GOSS covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given GOSS covered call is worth writing.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.
| 2028-01-21 | 498 | 1.00 | 614.29 | 0.05 | 0.15 | 91.00 | 650.00 | 476.41 | -35.71 | +0.82 | 880 | 0.10 |
| 2028-01-21 | 498 | 0.50 | 257.14 | 0.05 | 0.10 | 41.00 | 292.86 | 214.64 | -35.71 | +0.70 | 5,738 | 0.05 |
As of Sep 10, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank42.26% Moderate
- Market cap (M$)70
- 52 weeks high-96.38%
- 52 weeks low27.27%
- Analyst recommendationBuy
2.43 - Target price$1.66
-85.48% below the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-04
- P/E—
- Future P/E—
- EPS (ttm)-0.70
- EPS growth next 5 years46.48%
As of Nov 17, 2026